Cargando…
Naturally circulating dendritic cells to vaccinate cancer patients
Dendritic cell-based immunotherapy is a promising strategy against cancer that appears to be feasible, safe and to induce potent tumor-specific immune responses. The use of naturally circulating dendritic cells (DCs), rather than cultured monocyte-derived DCs, might constitute the next logical step...
Autores principales: | Bol, Kalijn F., Tel, Jurjen, de Vries, I. Jolanda M., Figdor, Carl G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661171/ https://www.ncbi.nlm.nih.gov/pubmed/23802086 http://dx.doi.org/10.4161/onci.23431 |
Ejemplares similares
-
Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy
por: Schreibelt, Gerty, et al.
Publicado: (2013) -
Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination
por: Aarntzen, Erik HJG, et al.
Publicado: (2013) -
CD56 marks human dendritic cell subsets with cytotoxic potential
por: Roothans, Dessie, et al.
Publicado: (2013) -
Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients
por: Bol, Kalijn, et al.
Publicado: (2015) -
Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy
por: Wimmers, Florian, et al.
Publicado: (2014)